| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9K | -85.5% | -63.0% |
| SG&A Expense | $1.2M | +248.8% | +484.5% |
| Operating Income | -$1.4M | -124.8% | -238.3% |
| Pre-tax Income | -$1.5M | -107.9% | -248.5% |
| Net Income | -$1.5M | -107.9% | -248.5% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.6M | +99.3% | +31.6% |
| Inventory | $29K | +322.2% | +322.2% |
| Current Assets | $1.6M | +95.5% | +32.5% |
| Total Assets | $2.4M | +48.1% | +16.3% |
| Current Liabilities | $10.2M | +1.5% | +9.0% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.3M | — | — |
| Capital Expenditures | $4K | — | — |
| Investing Cash Flow | $366K | — | — |
| Financing Cash Flow | $1.9M | — | — |
| Free Cash Flow | -$1.3M | — | — |
| — |
| $10.3M |
| +2.5% |
| +9.9% |
| Stockholders' Equity | -$8.0M | +6.1% | -8.1% |